A Phase 3 Study to Evaluate the Safety and Efficacy of AOC 1044 (Also Referred to as Delpacibart Zotadirsen) in Participants With DMD With Gene Mutations Amenable to Exon 44 Skipping
This study is a Phase 3 clinical trial testing a new medicine called AOC 1044, also known as delpacibart zotadirsen, for boys with Duchenne Muscular Dystrophy (DMD). It's specifically for those whose DMD is caused by a genetic change that could be helped by 'exon 44 skipping'. Researchers want to find out if this new medicine is safe and effective in slowing down the progression of DMD. Participants will receive either the real medicine or a placebo (a dummy medicine) through a drip. The study is designed to be very careful, checking health and progress over about two years, and then continuing with everyone receiving the active medicine.
De un vistazo
¿De qué trata este estudio?
This study is a major research project, known as a Phase 3 trial, designed to test a new medicine called AOC 1044 (you might also hear it called delpacibart zotadirsen). It's specifically for boys living with Duchenne Muscular Dystrophy (DMD). DMD is a serious muscle-wasting condition that gets worse over time. The goal of this research is to see if this new medicine can safely help with the condition and slow down its effects by targeting a specific genetic problem in some boys with DMD.
For most people with DMD, the body can't make a very important protein called dystrophin, which muscles need to work properly. This study focuses on boys whose DMD is caused by a genetic mistake that affects 'exon 44' of the dystrophin gene. The medicine, AOC 1044, is designed to 'skip' over this faulty part of the gene, allowing the body to produce a shorter, but still working, version of the dystrophin protein. This could potentially help muscles work better and be stronger.
Finding new treatments for DMD is very important to improve the quality of life for those affected. This study aims to gather strong evidence about whether AOC 1044 is a safe and effective option that could one day be available more widely.
Puntos clave
- This is a Phase 3 study for Duchenne Muscular Dystrophy (DMD) in boys aged 7-16.
- It tests a new medicine (AOC 1044) for a specific genetic type of DMD (exon 44 skipping).
- Participants will receive the medicine or a placebo by drip every 6 weeks.
- The study lasts over two years, with everyone getting the active medicine in the second year.
- It aims to see if the medicine is safe and can help improve muscle function.
- Strict eligibility rules apply, including your age and specific genetic test results.
¿Quién puede ser elegible?
This study is looking for boys with Duchenne Muscular Dystrophy (DMD) who meet certain requirements. They must be able to walk and have a clear diagnosis of DMD confirmed by genetic tests. Importantly, their genetic test results must show a specific type of mutation that the medicine is designed to target, known as 'exon 44 skipping'. Boys must be between 7 and 16 years old when they agree to take part, and they need to have been on a stable dose of steroid medication (including Vamorolone) for at least six months before starting the study.
There are also some reasons why someone might not be able to join. This includes boys who have previously had gene therapy or certain cell treatments. If they've had other similar types of medicine called 'oligonucleotides' in the last six months (not including COVID-19 vaccines), they also won't be able to join. Certain recent changes to other medications like growth hormone, testosterone, or givinostat might also prevent participation, as these need to be stable for a set period before the study starts. Regular blood tests and assessments will be done to ensure everyone is suitable and safe to participate.
¿Podría este estudio ser adecuado para ti?
Responde estas preguntas rápidas para ver si puedes ser elegible. Esto es solo una guía: el equipo de investigación toma la decisión final.
- Are you a boy with a confirmed diagnosis of Duchenne Muscular Dystrophy (DMD)?
- Does your genetic test show the 'exon 44 skipping' type of mutation?
- Are you currently able to walk?
- Are you between 7 and 16 years old?
- Have you been on a stable dose of steroid medication for at least 6 months?
- Have you *not* had gene therapy or certain cell treatments before?
¿En qué consiste la participación?
If you decide to take part, you'll first have a 'screening period' of up to 44 days to check if you're suitable. After that, you'll be randomly assigned to one of two groups for about a year (54 weeks). One group will receive the new medicine, AOC 1044, and the other will receive a placebo (a dummy medicine that looks the same but contains no active drug). Neither you, your family, nor the study doctors will know which you are receiving during this time.
The medicine (or placebo) will be given through a drip into your arm at the study clinic once every six weeks, for a total of nine doses. Throughout this period, you'll have regular visits for check-ups, assessments of your muscle strength and movement, and safety tests like blood samples. After this first year, everyone who wants to can enter an 'open-label' period. This means everyone will then receive the actual AOC 1044 medicine for another year (54 weeks), again given every six weeks for nine more doses. The final dose will be at around week 102, followed by a final health check-up a few weeks later, and then a safety follow-up visit. The total study duration, including follow-up, will be around two years and two months.
Riesgos y beneficios potenciales
Locations (20)
- The Children's Hospital at WestmeadCódigo postal verificadoWestmead, Australia· Reclutamiento
- UZ LeuvenCódigo postal verificadoLovaina, Bélgica· Reclutamiento
- Centre Hospitalier Régional de la CitadelleCódigo postal verificadoLieja, Bélgica· Reclutamiento
- London Health Sciences Centre - Victoria HospitalCódigo postal verificadoLondres, Canadá· Reclutamiento
- CHU de Nantes - Hotel-DieuCódigo postal verificadoNantes, France· Reclutamiento
- AP-HP Hospital Armand-TrousseauCódigo postal verificadoParís, Francia· Reclutamiento
- Universitaetsklinikum EssenCódigo postal verificadoEssen, Alemania· Reclutamiento
- Universitaetsklinikum HeidelbergCódigo postal verificadoHeidelberg, Alemania· Reclutamiento
- Klinikum der Ludwig-Maximilians-Universitaet MuenchenCódigo postal verificadoMúnich, Alemania· Reclutamiento
- Istituto Giannina GasliniCódigo postal verificadoGenova, Italy· Reclutamiento
- Fondazione Serena ETS - Centro Clinico NeMO MilanoCódigo postal verificadoMilan, Italy· Reclutamiento
- IRCCS Ospedale San RaffaeleCódigo postal verificadoMilan, Italy· Reclutamiento
Preguntas comunes
What is 'exon 44 skipping'?
It's a way the medicine tries to fix a specific genetic mistake in your DNA that causes DMD, by 'skipping over' the faulty part to help your body make a working muscle protein.
¿Qué es un 'placebo'?
A placebo is a dummy medicine that looks exactly like the real medicine but contains no active drug. It helps researchers compare how well the real medicine works.
¿Sabré si estoy recibiendo el medicamento real o el placebo?
During the first year, neither you nor your study doctor will know. This is to make sure results are fair. After that, everyone gets the real medicine if they choose to continue.
How is the medicine given?
The medicine is given through a drip into a vein, usually in your arm, at the study clinic once every six weeks.
¿Cuánto tiempo estaré en el estudio?
The study lasts for about two years and two months in total, including regular treatments, check-ups, and a final safety follow-up.
Cómo obtener más información
Avidity Bioscience, Inc., A Novartis Company
Siempre hable con su médico de cabecera o especialista antes de decidir participar en un estudio.
¿Interesado en participar?
Discusión
Discusión comunitaria
Impulsado por nuestro foro en community.patient.info. Por favor, sea respetuoso — esto no es un consejo médico.